- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04164849
Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid
January 29, 2024 updated by: Jørgen Jahnsen, University Hospital, Akershus
In the clinical trial the investigators will assess efficacy, safety and tolerability after single and multiple doses of 3 millimolar 5 aminolevulinic acid (Gliolan®) in combination with blue-light (405 nanometer) photopheresis in patients with active crohns disease.
The study is a proof-of-concept pilot with up to 10 included patients where every patient will get active treatment.
The use of 5-aminolevulinic acid in combination with blue-light photopheresis is a first-in-human trial.
Primary endpoints include clinical response and adverse events (safety).
Secondary endpoints include endoscopic improvement, quality of life questionnaires, faecal calprotectin, C-reactive protein and mechanisms of action (differences in t-cells and other cells before and after treatment).
All patients will get treatment every 2 weeks for 10 weeks (6 treatments-induction) with evaluation at week 13.
If any effect on week 13 eligible for study extension with treatment every 4 weeks for up to 12 months for the first 5 patients.
The latter 5 patients will be referred to standard of care on the week 13 visit.
Through the study the investigators will see if this kind of photopheresis is safe and can be an option for a larger randomized-controlled-trial.
In addition the investigators will see if photopheresis as an option can be further developed for other diseases as well (ie other T-cell mediated diseases or patients already receiving photopheresis as a treatment).
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jørgen Jahnsen, PhD
- Phone Number: +4767966013
- Email: jorgen.jahnsen@medisin.uio.no
Study Locations
-
-
Akershus
-
Lorenskog, Akershus, Norway, 1478
- Akershus University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of informed consent
- Age above 18
- Male or female patient with active Crohn's disease (6)
- Women of childbearing potential (WOCBP) will have to use highly effective methods of contraception throughout the entire study.
Inadequate response (a) or intolerance to biological therapy
a. Inadequate response on ongoing treatment is defined as: i. Progressive disease: increasing Harvey Bradshaw Index/Calprotectin/Simple Endoscopic Score for Crohns Disease and/or worsening of radiologic images after 6 months.
ii. Stable disease: no-response after 6 months
Active inflammation in the gut documented by
- Harvey Bradshaw Index >5 and
- Endoscopy with Simple Endoscopic Score for Crohns Disease equal to or above 6 points or equal to or above 4 points if only isolated ileitis is present and/or
- Inflammatory marker; fecal calprotectin > 250 and/or C reactive protein > 5
Exclusion Criteria:
- Photosensitive comorbidities, porphyria or known hypersensitivity to 5-aminolevulinic acid or porphyrins
- Patients with aphakia
- Pregnant or breast-feeding women. A negative urine pregnancy test must be demonstrated in female patients of child-bearing potential at the Screening Visit and before every treatment.
- Ongoing cardiac and pulmonary diseases or aspartate transaminase alanine aminotransferase, Bilirubin or International Normalized Ratio value ≥ 3x upper limit of normal or clinically significant electrocardiogram findings
- Subjects with polyneuropathy
- Uncontrolled infection or fever
- History of heparin-induced thrombocytopenia, absolute neutrophil count <1x109, platelet count <20x10 9
- Body weight below 40 kg
- Investigator considers subject unlikely to comply with study procedures, restrictions and requirements.
- Presence of other gastrointestinal diseases potentially influencing the study endpoints
- History of any clinically significant disease or disorder which in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result or the patient's ability to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 5-ALA photopheresis
All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light photopheresis.
The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes.
5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
|
5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
The treated cells are transferred back to the patient as a standard blood transfusion
The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol.
90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response
Time Frame: Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and 3 months after last treatment
|
Clinical response (Harvey Bradshaw Index change > 3 from baseline or less than 4 points)
|
Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and 3 months after last treatment
|
Safety and tolerability adverse events
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Frequency, seriousness and intensity of adverse events
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability Electrocardiogram-PR interval
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in PR interval before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability Electrocardiogram-PR segment
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in PR segment before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability Electrocardiogram-QT interval
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in QT interval before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability Electrocardiogram-ST segment
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in ST segment before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability Electrocardiogram-T wave
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in T wave before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability Electrocardiogram-QRS complex
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in QRS complex before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability vital signs
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Vital signs (heart rate) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Safety and tolerability blood pressure
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Vital signs (systolic and diastolic blood pressure) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Alkaline phosphatase
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in serum alkaline phosphatase (U/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Aspartate transferase
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in serum aspartate transferase(U/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Alanine aminotransferase
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in serum alanine aminotransferase (U/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Albumin
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Albumin (g/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Bilirubin
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Bilirubin (micromol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Gamma glutamyltransferase
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum gamma glutamyltransferase (U/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
White cell count
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood White cell count (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Neutrophil granulocytes
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood neutrophil granulocytes (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Lymphocytes
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Lymphocytes (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Monocytes
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Monocytes (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Eosinophile granulocytes
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Eosinophile granulocytes (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Basophile granulocytes
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Basophile granulocytes (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Platelet count
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Platelet count (10^9/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Mean Cell Volume
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Mean Cell Volume (fL) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Mean Cell hemoglobin
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Mean Cell hemoglobin (picogram) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
International Normalized Ratio
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood International Normalized Ratio (0,8-1,2) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Hemoglobin
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Blood Hemoglobin (g/dL) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Calcium
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Calcium (millimol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Potassium
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Potassium (millimol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Sodium
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Sodium (millimol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Creatinin
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Creatinine (micromol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Lactate Dehydrogenase
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Lactate Dehydrogenase (U/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Cholesterol
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Cholesterol (millimol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Total Protein
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Total Protein (g/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Carbamide
Time Frame: Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Changes in Serum Carbamide (millimol/L) before and after treatment
|
Before every treatment visit (every second week from week 0-10, every 4th week from week 14-62, week 28 for patients not eligible for study extension and latter 5 patients) in addition to week 64 and 3 months after last treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD4+ and CD8+ T cell subpopulations
Time Frame: Week 0, 10 (all patients) and 50 (patients of the first 5 subjects eligible for study extension)
|
Number of CD4+ and CD8+ T cell subpopulations before and after treatment assessed by flow cytometry.
|
Week 0, 10 (all patients) and 50 (patients of the first 5 subjects eligible for study extension)
|
Apoptosis and necrosis
Time Frame: Week 0, 10 (all patients) and 50 (patients of the first 5 subjects eligible for study extension)
|
Number of cells in apoptosis or necrosis before and after treatment assessed by flow cytometry
|
Week 0, 10 (all patients) and 50 (patients of the first 5 subjects eligible for study extension)
|
Clinical remission
Time Frame: Week 13 and/or sustained/delayed response in week 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and 3 months after last treatment.
|
Harvey Bradshaw Index < 5 points
|
Week 13 and/or sustained/delayed response in week 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and 3 months after last treatment.
|
Endoscopic efficacy
Time Frame: Week 13 (all patients) and 64 (patients of the first 5 subjects eligible for study extension) with baseline visit as reference.
|
Simple Endoscopic Score for Crohns Disease >49 % improvement or < 3 (endoscopic remission)
|
Week 13 (all patients) and 64 (patients of the first 5 subjects eligible for study extension) with baseline visit as reference.
|
Faecal calprotectin
Time Frame: Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Change from baseline
|
Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Concentration of C reactive protein in blood
Time Frame: Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Change from baseline
|
Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Quality of life questionnaire Short-Form 36 (SF-36)
Time Frame: Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Change of both total and subscores of SF-36 from baseline.
Min 0 Max 100.
Higher value is better quality of life.
|
Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Quality of life questionnaire Inflammatory Bowel Disease Questionnaire (IBDQ)
Time Frame: Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Change of both total and subscores of IBDQ from baseline.
Min 32 Max 224.
Higher value is better quality of life.
|
Week 13, 26 (28 for patients not eligible for study extension and the latter 5 patients), 38, 50, 64 and/or 3 months after last treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2019
Primary Completion (Actual)
October 31, 2023
Study Completion (Actual)
October 31, 2023
Study Registration Dates
First Submitted
November 8, 2019
First Submitted That Met QC Criteria
November 13, 2019
First Posted (Actual)
November 15, 2019
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- twostepala
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on 5-aminolevulinic acid
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
NorthShore University HealthSystemWithdrawn
-
medac GmbHCompletedBrain Cancer | Brain Tumors | Brain Tumor, Primary | Primary Brain Tumors | Cancer of Brain
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
St. Olavs HospitalOslo University Hospital; Norwegian University of Science and TechnologyCompletedCutaneous T-Cell Lymphoma, Unspecified | Chronic Graft Versus Host Disease in SkinNorway
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting
-
medac GmbHIKPCompleted
-
Southern Illinois UniversityDUSA Pharmaceuticals, Inc.CompletedBrain NeoplasmsUnited States
-
Andrew Sloan, MDCompletedBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedGlioma | AstrocytomaUnited States